10:42 AM EST - Bausch Health Companies Inc. : Today announced expanded public reimbursement for PrOKEDI® (extended-release injectable suspension of risperidone) 75 mg and 100 mg, with coverage now available for eligible patients, subject to the applicable reimbursement criteria, through public drug plans in seven provinces and multiple federal drug plans. Bausch Health Companies Inc.
shares T.BHC are trading up $0.03 at $8.95.
